| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of
*
Ophthalmology and Visual Sciences and
Pathology, Washington University School of Medicine, St. Louis, MO 63110; and
Institute of Biochemistry, University of Lausanne, Epalinges, Switzerland
Fas ligand (FasL, CD95L) expression helps control inflammatory reactions in immune privileged sites such as the eye. Cellular activation is normally required to render lymphoid cells sensitive to FasL-induced death; however, both activated and freshly isolated Fas+ lymphoid cells are efficiently killed in the eye. Thus, we examined factors that might regulate cell death in the eye. TNF levels rapidly increased in the eye after the injection of lymphoid cells, and these cells underwent apoptosis within 24 h. Coinjection of anti-TNF Ab with the lymphoid cells blocked this cell death. Furthermore, TNFR2-/- T cells did not undergo apoptosis in the eyes of normal mice, while normal and TNFR1-/- T cells were killed by apoptosis. In vitro, TNF enhanced the Fas-mediated apoptosis of unactivated T cells through decreased intracellular levels of FLIP and increased production of the pro-apoptotic molecule Bax. This effect was mediated through the TNFR2 receptor. In vivo, intracameral injection of normal or TNFR1-/- 2,4,6-trinitrophenyl-coupled T cells into normal mice induced immune deviation, but TNFR2-/- 2,4,6-trinitrophenyl-coupled T cells were ineffective. Collectively, our results provide evidence of a role for the p75 TNFR in cell death in that TNF signaling through TNFR2 sensitizes lymphoid cells for Fas-mediated apoptosis. We conclude that there is complicity between apoptosis and elements of the inflammatory response in controlling lymphocyte function in immune privileged sites.
This article has been cited by other articles:
|
|
 |
|
  M. A. Niewczas, L. H. Ficociello, A. C. Johnson, W. Walker, E. T. Rosolowsky, B. Roshan, J. H. Warram, and A. S. Krolewski Serum Concentrations of Markers of TNF{alpha} and Fas-Mediated Pathways and Renal Function in Nonproteinuric Patients with Type 1 Diabetes Clin. J. Am. Soc. Nephrol., January 1, 2009; 4(1): 62 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ismail, E. C. Crossley, H. L. Stevenson, and D. H. Walker Relative Importance of T-Cell Subsets in Monocytotropic Ehrlichiosis: a Novel Effector Mechanism Involved in Ehrlichia-Induced Immunopathology in Murine Ehrlichiosis Infect. Immun., September 1, 2007; 75(9): 4608 - 4620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Greenfeld, K. F. Roby, M. E. Pepling, J. K. Babus, P. F. Terranova, and J. A. Flaws Tumor Necrosis Factor (TNF) Receptor Type 2 Is an Important Mediator of TNF alpha Function in the Mouse Ovary Biol Reprod, February 1, 2007; 76(2): 224 - 231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Kemp, A. T. Ludwig, J. K. Earel, J. M. Moore, R. L. VanOosten, B. Moses, K. Leidal, W. M. Nauseef, and T. S. Griffith Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L Blood, November 15, 2005; 106(10): 3474 - 3482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Depuydt, G. Van Loo, P. Vandenabeele, and W. Declercq Induction of apoptosis by TNF receptor 2 in a T-cell hybridoma is FADD dependent and blocked by caspase-8 inhibitors J. Cell Sci., February 1, 2005; 118(3): 497 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-Y. Qin, P. Chaturvedi, and B. Singh In vivo apoptosis of diabetogenic T cells in NOD mice by IFN-{gamma}/TNF-{alpha} Int. Immunol., December 1, 2004; 16(12): 1723 - 1732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Rutigliano and B. S. Graham Prolonged Production of TNF-{alpha} Exacerbates Illness during Respiratory Syncytial Virus Infection J. Immunol., September 1, 2004; 173(5): 3408 - 3417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Murray and I. N. Crispe TNF-{alpha} Controls Intrahepatic T Cell Apoptosis and Peripheral T Cell Numbers J. Immunol., August 15, 2004; 173(4): 2402 - 2409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Y. Niederkorn, E. Mayhew, J. Mellon, and S. Hegde Role of Tumor Necrosis Factor Receptor Expression in Anterior Chamber-Associated Immune Deviation (ACAID) and Corneal Allograft Survival Invest. Ophthalmol. Vis. Sci., August 1, 2004; 45(8): 2674 - 2681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Umemura, T. Kawabe, K. Shudo, H. Kidoya, M. Fukui, M. Asano, Y. Iwakura, G. Matsuzaki, R. Imamura, and T. Suda Involvement of IL-17 in Fas ligand-induced inflammation Int. Immunol., August 1, 2004; 16(8): 1099 - 1108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. K.-M. Chan, J. Shisler, J. G. Bixby, M. Felices, L. Zheng, M. Appel, J. Orenstein, B. Moss, and M. J. Lenardo A Role for Tumor Necrosis Factor Receptor-2 and Receptor-interacting Protein in Programmed Necrosis and Antiviral Responses J. Biol. Chem., December 19, 2003; 278(51): 51613 - 51621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Droin, M. J. Pinkoski, E. Dejardin, and D. R. Green Egr Family Members Regulate Nonlymphoid Expression of Fas Ligand, TRAIL, and Tumor Necrosis Factor during Immune Responses Mol. Cell. Biol., November 1, 2003; 23(21): 7638 - 7647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. I. Kafrouni, G. R. Brown, and D. L. Thiele The role of TNF-TNFR2 interactions in generation of CTL responses and clearance of hepatic adenovirus infection J. Leukoc. Biol., October 1, 2003; 74(4): 564 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Malewicz, N. Zeller, Z. B. Yilmaz, and F. Weih NF{kappa}B Controls the Balance between Fas and Tumor Necrosis Factor Cell Death Pathways during T Cell Receptor-induced Apoptosis Via the Expression of Its Target Gene A20 J. Biol. Chem., August 29, 2003; 278(35): 32825 - 32833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Pinkoski, N. M. Droin, and D. R. Green Tumor Necrosis Factor alpha Up-regulates Non-lymphoid Fas-ligand following Superantigen-induced Peripheral Lymphocyte Activation J. Biol. Chem., October 25, 2002; 277(44): 42380 - 42385. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
